Committee Meeting Updates

September 3, 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 In continuation of the Company's disclosures dated December 7, 2024 and December 21, 2024 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) (the "Company" or "Cohance") wishes to inform that, in accordance with the in-principle approval accorded and powers delegated by the Board of Directors (“Board”) of the Company, the Investment, Banking and Authorisations Committee (IBA Committee) of the Board, at its meeting held today, i.e. September 3, 2026, has considered and approved the following as part of a proposed reorganisation at: (i) NJ Bio, Inc. (“NJ Bio”), a subsidiary of the Company: for the acquisition of an additional 244,587 shares of common stock in NJ Bio at USD 53.00 per share (aggregate consideration of approximately USD 13 million), increasing the Company's stake from 56% to 67.3%. Dr. Naresh Jain will continue as CEO of NJ Bio, retaining 32.7% of NJ Bio's equity. (ii) Aruka Bio, Inc. (“Aruka Bio”), a step-down associate of the Company: for subscribing (either directly or through its nominated subsidiary) shares of Aruka Bio, which is an innovative platform focusing on novel ADC therapies, for approximately USD 5 million, acquiring approximately 65%. Dr. Naresh Jain will also assume the role of CEO at Aruka Bio. This reorganisation reinforces Cohance’s commitment to the ADC space through closer integration of NJ Bio’s customer-facing capabilities with Cohance’s manufacturing platform, while positioning Aruka Bio to advance its proprietary pipeline through potential development partnerships. The closer integration of NJ Bio with Cohance is expected to strengthen business performance across the combined platform over time. The NJ Bio transaction is subject to the execution of amended and restated agreements, and the Aruka Bio transaction is subject to the execution of definitive agreements, in each case subject to receipt of applicable regulatory approvals and customary closing conditions. A copy of the press release being issued in this regard is enclosed herewith. The disclosures pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are set out in Annexure-A (NJ Bio) and Annexure-B (Aruka Bio). The IBA Committee meeting commenced at 4.00 p.m. (IST) and was concluded at 4.55 p.m. (IST). This is for your information and records. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K Mishra Company Secretary & Compliance Officer Encl: As above. Cohance Lifesciences advances its ADC strategy Investment of USD 18 million in NJ Bio and Aruka Bio September 03, 2026: Cohance Lifesciences Limited today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals. The re-organisation establishes distinct priorities: deeper integration of NJ Bio’s customer- facing services with Cohance, and focused development of Aruka’s proprietary pipeline through potential partnerships. NJ Bio: planned succession, continued founder engagement Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Ms. Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%. Dr. Jain will continue to lead NJ Bio while also advancing Aruka’s pipeline and partnership initiatives. NJ Bio will remain focused on customer-facing contract research, development and manufacturing services. Closer integration will combine its payload-linker and bioconjugation expertise with Cohance’s manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time. Aruka Bio: control of the platform, development with partners Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Its lead program is currently at the preclinical stage. Press Release Cohance’s USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital. Following completion and Dr. Jain’s upfront equity grant, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr. Jain. These percentages are before further dilution from Dr. Jain’s performance-linked equity award. Aruka will become Cohance’s direct subsidiary. The investment consolidates control of Aruka’s proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses. This follows a review of NJ Bio's performance and integration with Cohance since the original investment in December 2024, which identified an opportunity to strengthen commercial alignment between the two businesses as NJ Bio expands its GMP CDMO services and to give dedicated leadership focus to Aruka's novel drug development pipeline. Completion is expected by the end of September 2026, subject to definitive agreements, applicable approvals and customary closing conditions. Dr. Naresh Jain, Founder and CEO, NJ Bio, said: “I will work across both businesses— supporting NJ Bio’s growth and an orderly leadership handover, while working together with Cohance in advancing Aruka’s pipeline and exploring development partnerships. Thereafter, I will focus full-time on Aruka as CEO, while continuing to support NJ Bio as a strategic advisor.” Umang Vohra, Executive Chairman and Group CEO, Cohance Lifesciences, said: “This reorganisation gives each business a clear focus: strengthening NJ Bio’s customer offering through closer integration with Cohance and creating the opportunity for Dr Jain to lead Aruka’s next phase. This integration is expected to strengthen business performance across the combined platform over time” -ENDS- Press Release About Cohance Lifesciences Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. Leveraging a combined platform with state-of-the-art facilities in India and the U.S., Cohance delivers integrated solutions from early development to commercial supply for leading global pharma companies. For more information, please contact: www.cohance.com Cyndrella Carvalho, Head - Investor Relations, Gavin Desa / Konpal Pali Cohance Lifesciences Limited CDR India Tel: 040 2354 3311 Tel: +91 98206 37649/ +91 76619 08341 Email: cyndrella.carvalho@cohance.com Email: gavin@cdr-india.com; konpal@cdr-india.com Disclaimer: This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to media or reproduced in any form, without prior written consent Cohance Lifesciences. This document is based on information obtained from public sources and sources bel [Showing first 8,000 characters — download PDF for full document]